StemCell Therapy

With Amy Hess-Fischl RD

It's no secret that people with type 2 diabetes are at an increased risk for major health complications. But one class of medicine might be able to change that, researchers say. According to a recent studypublished in the British Medical Journal (BMJ), a type of medication called SGLT2 inhibitors reduced the risk of heart failure and stroke among patients with type 2 diabetes, suggesting they have cardio-protective benefits.

Otherwise known as sodium glucose co-transporter 2 inhibitors,SGLT2 inhibitorsare a class of medication, delivered in pill form, that can help lower blood glucose levels in diabetic patients.

SGLT2 inhibitors are a relatively new class of medication that can have really impressive results, says Amy Hess-Fischl RD, a certified diabetes educator at the University of Chicago. While most diabetes medications either increase insulin or insulin sensitivity, SGLT2 inhibitors cause the kidneys to excrete glucose into the urine, preventing it from being reabsorbed back into the bloodstream.

By decreasing blood sugar levels, SGLT2 inhibitors can help improve your A1C levels as well, and potentially even aid in medically advised weight loss. According torecent research from Johns Hopkins University, SGLT2 inhibitors typically improve A1C levels anywhere from 0.5% to 1% when taken daily over the course of six months.

Because SGLT2s help decrease sugar in the blood, this also helps reduce some of the complications and long-term damage that can come from having high blood sugar.

Glucose is very attracted to hemoglobin, which is in our red blood cells, says Fischl. The more sugar we have in our blood, the more it can attach to the hemoglobin, and the harder our red blood cells get. Those hard red blood cells, pounding up against our blood vessels for years on end, can cause a lot of damage.

One recent study published in the 2019 issue of theNew England Medical Journal(NEJM) found that the risk of renal failure was 30 percent lower in patients with type 2 diabetes who took the SGLT2 inhibitor Canagliflozin, compared with patients in the control group who took a placebo.

The latest research, published in the September 2020 issue of theBritish Medical Journal(BMJ), reinforces what earlier studies have shown: SGLT2s can protect against heart attack, heart failure, and stroke among patients with type 2 diabetes.

The study authors used five years of healthcare data from type 2 diabetes patients across Canada and the United Kingdom. They surveilled over 200,000 patients who took SGLT2 inhibitors and compared them to the same number of patients who took another class of medication known as DPP-4 inhibitors. (DPP-4s help reduce blood sugar levels in diabetic patients by increasing insulin.) The researchers then recorded any major cardiac events such as heart attack, stroke, and heart failure for an average of 11 months.

The results showed that SGLT2 inhibitors were associated with a lower risk of cardiac events in type 2 diabetics when compared to DPP-4 inhibitors. For example, the rate of heart failure was 3.1 events per 1,000 people among patients who took SGLT2s and 7.7 events per 1,000 people among patients who took DPP-4s. Heart attacks, strokes, and overall mortality rates were also lower in patients who took SGLT2s. These results were consistent across age, sex, past insulin use, and history of cardiovascular disease, the study found.

While the new study produced notable results, it also has some limitations. Observational studies are just that observational, according to Hess-Fischl. They're nice because they give researchers a place to start, but we really need comparative data next.

Additionally, while it may be true that SGLT2s have some cardioprotective benefit, people with type 2 diabetes should be aware that the medication is not without risk.

What we've been finding is that SGLT2s tend to increase the risk of a condition called Euglycemic Diabetic Ketoacidosis, which is a life-threatening condition caused by a buildup of ketones in the bloodstream," Hess-Fischl says. SGLT2s can also cause urinary tract infections particularly in females due to increased sugar being excreted in urine. They are also contraindicated for patients in kidney failure.

All in all, Fischl says, while SGLT2s can be a godsend for some patients with type 2 diabetes, they're far from a miracle drug. More research, such as double-blind placebo studies, is still needed to determine whether or not they can truly guard against cardiac events.

Last updated on 10/20/2020

All About Type 2 Diabetes

Read more from the original source:
SGLT2 Inhibitors Shown to Reduce Risk of Heart Attacks and Strokes in People with Type 2 Diabetes - EndocrineWeb

Dr Masakazu Aihara

Measuring glycated albumin (glycoalbumin, GA) in tears could be a future way for those with diabetes to monitor their blood sugar levels noninvasively.

In a 100-patient trial, levels of GA in tears were found to be strongly correlated (r = .722;P< .001) with those in the blood.

"GA levels in blood are widely measured in clinical practice in Japan," said study investigator Masakazu Aihara, MD, PhD, in an interview.

"It's a biomarker that reflects the 2-week average blood glucose level like fructosamine," explained the researcher from the department of diabetes and metabolic diseases in the Graduate School of Medicine at the University of Tokyo.

This could make it a better biomarker for detecting earlier changes in blood glucose than glycated hemoglobin (HbA1c), which reflects changes in blood glucose over the preceding 2-3 months.

Prior studies had shown that glucose levels can be measured in tear samples and that tear glucose levels correlated with blood glucose levels, Aihara and fellow researchers observed in a poster presentation at the virtual annual meeting of the European Association for the Study of Diabetes.

"While looking for noninvasive diabetes-related markers, we found that tears contained albumin. Based on this fact, we thought that GA could be measured in tears," Aihara explained.

Usingtears to test for biomarkersis not a new idea tears not only protect the eye, they contain a variety of large proteins, and their composition can change with disease. Indeed, researchers have been looking at their usefulness in helping find biomarkers forParkinson's diseaseanddiabetic peripheral neuropathy.

Duringtheir study, Aihara and associates collected tear and blood samples at the same time. Tear samples were assessed using liquid chromatography (LC) and mass spectrometry (MS). An enzymic method was used to measure GA levels in blood. Several diagnosis assay kits for GA are sold in Japan, Aihara said, and at leastone of thesehas U.S. Food and Drug Administration approval.

Multiple regression analysis revealed that the correlation between GA levels in tears and in blood was maintained even after adjustment for age, gender, nephropathy stage, and obesity (P< .001). The results obtained from the tests were thought unlikely to be affected by any changes in the concentration or dilution of tear samples.

"Since GA levels in blood are clinically used in all types of diabetes, GA levels in tears is also expected to be useful in all types of diabetes," Aihara said, noting that the effects of receiving treatment on GA levels in tears is something that he would like to look at.

The team would also like to optimize how tear samples are collected and reduce the volume of tears that are required for analysis. At the moment tears are collected via a dropper and about 100 mcL of tear fluid is required for measurement.

"At present, it is difficult to measure for dry eye patients because sufficient tears cannot be collected, but if the required amount of tears decreases in the future, it may be indicated for dry eye patients," Aihara noted.

Discussing further research plans, he added: "We would like to examine the conditions of LC-MS/MS so that the correlation coefficient with GA in blood can be improved.

"Since LC-MS/MS is a large equipment in the laboratory, I would like to develop a device that can measure at the clinic or at home in the future."

The study was funded by a grant from the Japan Agency for Medical Research and Development. Aihara had no conflicts of interest.

SOURCE:Aihara M et al. EASD 2020,poster presentation 624.

This article originally appeared on MDedge.com, part of the Medscape Professional Network.

Follow this link:
Substance in Tears Could Be Used for Diabetes Monitoring - Medscape

Celiac.com 10/20/2020 - Doctors diagnosing children for type 1 diabetes are increasingly finding other autoimmune conditions that can complicate the outlook for these patients. A team of researchers recently set out to study rates of comorbid autoimmune diseases, including celiac disease, and type 1 diabetes mellitus (T1D) in children.

Rates of type 1 diabetes mellitus (T1D) in children are on the rise, but it's unclear what relationship, if any, this might have with other coexistent autoimmune conditions, since diabetes onset is not well understood.

The team studied 264 boys and 229 girls between 0 and 18 years old with newly diagnosed with T1D in one of the Polish centers from 20102018. They determined diagnoses for related autoimmune illnesses from initial data recorded when patients first received diagnosis for T1D.

The team found that the standardized incidence rate of T1D in children rose 170% over the 9-year study period, while the incidence rate ratio rose 4% per year.

As rates of T1D have risen rapidly in all children of all ages in recent years, so, too have rates of the autoimmune diseases that frequently accompany these conditions. Having an additional autoimmunity disorder is a serious burden for patients with new-onset T1D.

Stay tuned for more information on the challenges faced by children with more than one auto-immune disease.

Read more in Front Endocrinol (Lausanne). 2020; 11: 476.

Reference:Gowiska-Olszewska B, Szabowski M, Panas P, et al. Increasing co-occurance of additional autoimmune disorders at diabetes type 1 onset among children and adolescents diagnosed in years 2010-2018single-center study. Front Endocrinol. Published online August 6, 2020. doi:10.3389/fendo.2020.00476

The research team included Barbara Gowiska-Olszewska,Maciej Szabowski,Patrycja Panas,Karolina oadek,Milena Jamiokowska-Sztabkowska,Anna Justyna Milewska,Anna Kadubiska,Agnieszka Polkowska,Wodzimierz uczyski,and Artur Bossowski. They are variously affiliated with the Department of Pediatrics, Endocrinology, Diabetology With Cardiology Division, Medical University of Bialystok, Biaystok, Poland; the Department of Pediatrics, Rheumatology, Immunology and Metabolic Bone Diseases, Medical University of Bialystok, Biaystok, Poland; the Department of Statistics and Medical Informatics, Medical University of Bialystok, Biaystok, Poland; and the Department of Medical Simulations, Medical University of Bialystok, Biaystok, Poland.

Read the rest here:
Kids with Type 1 Diabetes Increasingly Have Other Autoimmune Diseases - Celiac Disease and Gluten-Free Diet Support - Celiac.com

Know someone with diabetes? Have it yourself? If so, youre not alone.

One in 11 American has diabetes, and one in three has prediabetes.

Managing this disease will help prevent damage to your heart, eyes and nerves over time, says Kristin Bogdonas, a nutrition and wellness educator for University of Illinois Extension.

Bogdonas is offering two Tools to Manage Diabetes workshops in the month of November that will introduce participants to some tools that can help manage carbohydrate intake and plan meals effectively.

One program is online, and the other is in person.

The Tools to Manage Diabetes online program will be 4 to 5 p.m. Tuesday, Nov. 10, via Zoom.

This program is free and offered in conjunction with the Rock Island Public Library.

Once registered, participants will pick up their class materials from the main library, located at 401 19th St., Rock Island.

Class size is limited to 20.

The Tools to Manage Diabetes in-person program will be 1 to 2 p.m. Wednesday, Nov. 11, at the Rock Island County Extension, located at 321 2nd Ave. West, Milan.

There is a $5 cost to attend, and class size is limited to eight persons.

Masks will be required, and social distancing will be practiced.

Space is limited and available on a first-come, first-served basis.

Register through the University of Illinois Extension events page by Monday, Nov. 9.

Participants will receive a diabetes portion plate, carbohydrate counting pocket guide and presentation handouts.

These class materials are funded in part by a City of Rock Island Gaming Grant.

More information about University of Illinois Extension is here.

Go here to see the original:
Need help managing diabetes? A local nutrition and wellness educator is offering guidance - WHBF - OurQuadCities.com

Respondents recognize the importance of tracking their insulin data over time but admit to being too busy and/or forgetting to log their insulin use about eight times within the past month.

Respondents believe technology can help them more effectively manage their condition.

CHICAGO, Oct. 19, 2020 /PRNewswire/ -- The Association of Diabetes Care & Education Specialists (ADCES) today announced the results of a national survey that uncovered people living with diabetes are challenged by tracking information related to their condition over time. The survey found that while 65 percent of respondents report they are doing everything they possibly can to manage their diabetes, just as many (67 percent) feel guilty about not doing a better job. The national survey was supported by Sanofi US.

More than 30 million people have diabetes in the U.S., and for those who take insulin and have been trained on the self-adjustment of doses glucose (blood sugar) readings offer the opportunity to address out-of-range glucose levels. The survey showed that people living with diabetes, who track their insulin use, recognize the importance of looking back at their data over time, but nearly two-thirds agree it would be more helpful if there were better tools for doing it. When citing the most common challenges they have had in tracking their insulin use over a month's time, 62 percent of respondents reported being too busy to log and/or forgetting to log their insulin use.

"The management of diabetes is complex and so deeply personal that people living with diabetes often need to make drastic changes to their lifestyle, relearning their body's needs at the most basic level," said Lorena Drago, MS, RDN, CDN, CDCES and multi-cultural nutrition education expert. "Since the changes people make can impact every area of their lives, I understand why respondents may feel that they are doing all that they can to manage their diabetes, while at the same time still believing they are still not doing enough. The complex nature of managing diabetes presents an opportunity for healthcare professionals to personalize diabetes management. One way to personalize diabetes management is to collect useful diabetes information automatically in one place."

Story continues

Challenges with Tracking Data Over Time & Benefit of Added TechnologyWhile there are several methods available to manage diabetes information, including tracking glucose levels and insulin use, there is still room for improvement. For example:

Among people who track their blood glucose levels with a blood glucose monitor or continuous glucose monitor, 47 percent feel their current method of tracking glucose levels is simple and easy to do, while also wishing it was even more simple and easy to do.

Similarly, among people who currently track their insulin use, 45 percent agree that looking back at their insulin use and how it impacts their glucose levels is easy to do, but they still desire it to be easier.

When considering what could make tracking their diabetes information easier, the survey revealed people living with diabetes wish all their data was put together automatically so they could see everything they need in one place (82 percent). In particular, the vast majority of respondents (more than 80 percent) believe a device which connects to an insulin pen, automatically tracks/records insulin use and wirelessly sends the information to an app on a smartphone or tablet, would be helpful in more effectively managing their diabetes.

"Given the personal nature of diabetes, and the constant management needed, these data truly underscore the challenges people face in tracking and managing diabetes information. These data also show the potential benefits of integrating technology into the care routines of people living with diabetes," said Kellie Antinori-Lent, MSN, RN, ACNS-BC, BC-ADM, CDCES, FADCES and president of ADCES. "My goal as a diabetes care and education specialist is to help overcome the challenges of managing diabetes and it is my belief that tools which automate this process may not only improve the individual's understanding of their condition, but can inform care providers in efficient patient management."

Measuring glucose accurately and logging insulin data is the first step in the wellbeing and care of a person living with diabetes. The potential benefits of a device that automatically brings diabetes data together for people living with diabetes range from having better conversations with their provider and health care team to improving the accuracy of managing or tracking insulin use. Specifically, respondents of the survey living with diabetes would find such a device helpful in:

Giving them a more personalized understanding of their diabetes (79 percent)

Making managing or tracking insulin use less time consuming (78 percent)

Making them feel more empowered when it comes to managing diabetes (75 percent)

"These findings highlight the ongoing need to provide support to people living with diabetes," said Rogelio Braceras, MD, North America Medical Head of General Medicines, Sanofi. "We are proud to be collaborating with ADCES to better understand this population's unmet needs and bring them to the forefront to inform and ultimately help advance personalized care for people living with diabetes."

The national survey was conducted by a market research firm in June and July of 2020 and included more than 700 American adults living with Type 1 or Type 2 diabetes who take insulin. All respondents were taking insulin that was administered with a vial/syringe or pen regularly for at least six months. Respondents were not excluded if they delivered their insulin via an insulin pump or if they also used inhaled insulin.

About the Association of Diabetes Care & Education Specialists: ADCES is an interdisciplinary professional membership organization dedicated to improving prediabetes, diabetes and cardiometabolic care through innovative education, management and support. With more than 12,000 professional members including nurses, dietitians, pharmacists and others, ADCES has a vast network of practitioners working to optimize care and reduce complications. ADCES supports an integrated care model that lowers the cost of care, improves experiences and helps its members lead so better outcomes follow. Learn more at DiabetesEducator.org, or visit us on Facebook or LinkedIn (Association of Diabetes Care & Education Specialists), Twitter (@ADCESdiabetes) and Instagram (@ADCESdiabetes).

About Sanofi:Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

Contact:Matt Eaton, 312-601-4866, meaton@adces.org

View original content to download multimedia:http://www.prnewswire.com/news-releases/national-survey-reveals-people-living-with-diabetes-feel-they-are-doing-everything-they-can-to-manage-their-condition-yet-believe-more-can-be-done-301154175.html

SOURCE Association of Diabetes Care & Education Specialists

Here is the original post:
National Survey Reveals People Living with Diabetes Feel They Are Doing Everything They Can to Manage Their Condition, Yet Believe More Can Be Done -...

BERLIN Coos County Family Health Services has begun offering specialized support services to people living with diabetes.

Heather Beaudry, RN, will lead this new program as part of her work as a certified diabetes care and support specialist. The program is newly accredited by the Association of Diabetes Care & Education Specialists, and is available to all Coos County Family Health Servicespatients.

Our mission is to help people living with diabetes gain control of their illness, and live full and active lives, said Beaudry. Diabetes is a chronic illness that poses many challenges. We can help people with the skills and knowledge they need to improve their health.

The program will be offered at the organizations Pleasant Street Clinic on Monday through Thursday, from 8 a.m.-5 p.m. The service is covered by most insurances, and can be provided on a discounted basis for those in need. Diabetes education is a covered Medicare benefit when delivered through an accredited program.

Diabetes is one of the most common and significant illnesses affecting older adults in our community, said Patty Couture, Coos County Family Health Serviceschief operating officer.

Diabetes education services utilize a collaborative process through which people with diabetes work with a Certified Diabetes Care and Education Specialist to receive individualized care to help them reach their health goals.

Programs like the one we have established can help people with diabetes improve their health and to live long and productive lives, said Beaudry.

For more information about the program, or to schedule a time to meet with Heather Beaudry, contact any of the Family Health Clinics or call (603) 752-2040.

Go here to read the rest:
Coos Family Health to offer specialized support to those living with Diabetes - Berlindailysun

IndustryGrowthInsights (IGI), a prominent market research firm in its own industry, has published a detailed report on Global Diabetes Treatment Market. This market research report provides comprehensive and in-depth analysis on the market which can possibly help an enterprise to identify lucrative opportunities and assist them with fabricating creative business strategies. The market report provides information about the current market scenario regarding the global supply and demand, key market trends and opportunities in the market, and challenges and threats faced by the industry players.

The Diabetes Treatment market report talks about the competitive scenario among the industry players and imparts aspiring and emerging industry players with the future market insights in a detailed manner. This market report includes crucial data and figures which are structured out in a concise yet understandable manner. The research report covers the updates on the government regulations and policies which illustrates key opportunities and challenges of the market. IndustryGrowthInsights (IGI) has been monitoring the market since few years and collaborated with eminent players of the industry to give better insights on the market. It has conducted vigorous research and implied robust methodology to provide accurate predictions about the market.

You can buy the complete report on @ https://industrygrowthinsights.com/checkout/?reportId=186783

Impacts of Advancements and COVID-19 on the market.

Amidst the COVID-19, few segments of the market have witnessed a disruption due to the gap in supply and demand which has impacted the growth of the Diabetes Treatment market. Along with this, the latest advancements have changed the market dynamics of the market. This research report covers the wide-range analysis of the COVID-19 impact to the industry and gives out insights on the change in the market scenario due to the advancements.

Get Exclusive Free Sample Report @ https://industrygrowthinsights.com/request-sample/?reportId=186783

Market Segmentation

Some of the major companies that are covered in the report.

Novo NordiskBayerTeva Pharmaceuticals Pvt Ltd.MerckCompany Inc.Medtronic Inc.JohnsonJohnsonHome Diagnostics Inc.Amylin Pharmaceuticals Inc.Abbott Laboratories

Note: Additional companies

Based on the type, the market is segmented into

InsulinOral Hypoglycaemic DrugsNon-Insulin Injectable Drugs

Based on the application, the market is segregated into

HospitalPersonal UseClinic

Based on the geographical location, the market is segregated into

Asia Pacific: China, Japan, India, and Rest of Asia PacificEurope: Germany, the UK, France, and Rest of EuropeNorth America: The US, Mexico, and CanadaLatin America: Brazil and Rest of Latin AmericaMiddle East & Africa: GCC Countries and Rest of Middle East & Africa

IndustryGrowthInsights (IGI) provides yearly updates on the Diabetes Treatment market that assist the clients to stay ahead in the competitive space.

Why one should buy this Diabetes Treatment Report?

The market research report provides all valuable constituents of the market such as revenue growth, product pricing & analysis, growth potential, and guidelines to tackle the challenges in the market. The report covers all the crucial mergers & acquisitions, partnerships, and collaborations that created further created opportunities or in some cases, challenges for the industry players.

This report includes latest product news, advancements, and updates from the prominent player of the industry that has leveraged their position in the market. It also provides business strategies implemented by the key players and yardstick to arrive on informed business decisions. Moreover, it gives insights on the consumer behavior patterns that can help the enterprise to curate the business strategies accordingly.

IndustryGrowthInsights (IGI) bestows the clients with the specialized customized options related to the regional analysis, company analysis, and product analysis, among others.

Complete Table Content of the Market

Executive Summary

Assumptions and Acronyms Used

Research Methodology

Diabetes Treatment Market Overview

Diabetes Treatment Supply Chain Analysis

Diabetes Treatment Pricing Analysis

Global Diabetes Treatment Market Analysis and Forecast by Type

Global Diabetes Treatment Market Analysis and Forecast by Application

Global Diabetes Treatment Market Analysis and Forecast by Sales Channel

Global Diabetes Treatment Market Analysis and Forecast by Region

North America Diabetes Treatment Market Analysis and Forecast

Latin America Diabetes Treatment Market Analysis and Forecast

Europe Diabetes Treatment Market Analysis and Forecast

Asia Pacific Diabetes Treatment Market Analysis and Forecast

Middle East & Africa Diabetes Treatment Market Analysis and Forecast

Competition Landscape

If you have any questions on this report, please reach out to us @ https://industrygrowthinsights.com/enquiry-before-buying/?reportId=186783

About the Company

IndustryGrowthInsights (IGI) is the largest aggregator of the market research report in the industry with more than 800 global clients. The company has extensively invested in the research analysts training and programs to keep the analyst tapped with the best industry standards and provide the clients with the&utmost experience. Our dedicated team has been collaborating with the industry experts to give out the precise data and figures related to the industry. It conducts primary research, secondary research, and consumer surveys to provide an in-depth analysis of the market. The market research firm has worked in several business verticals and has been successful to earn high credentials over the time.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 545 6473Email: [emailprotected]Website: https://industrygrowthinsights.com

Continue reading here:
Growth Of Diabetes Treatment Market In Global Industry: Overview, Size And Share 2020-2027 - The Think Curiouser

As a public service, Shaw Media will provide open access to information related to the COVID-19 (Coronavirus) emergency. Sign up for the newsletter here

Dr. Tiffany E. Groen likened learning about the coronavirus as running across a bridge while trying to build it.

Its amazing how differently the virus affects people, Groen said. It might give one person respiratory issues. Another person might have no respiratory issues but have blood clots.

But one thing appears clear. Having diabetes is a risk factor for severe COVID-19.

People with diabetes arent necessarily more at catching the virus, according to the American Diabetes Association.

But they do have increased risk for severe complications, especially if they have other conditions, too, such as heart disease, the ADA said.

There is not enough evidence that having diabetes will increase the risk of contracting the virus, Dr. Babak Pazooki, an endocrinologist with AMITA Health Saint Joseph Medical Center in Joliet, said. But there is enough evidence to support the notion that if you have diabetes, your outcome may be worse.

In fact, diabetics are at risk of complications when they contract any virus, the ADA said.

Diabetics are also at greater risk of acquiring and having worse outcomes certain infections, such as urinary tract and respiratory infections, Pazooki said

Groen said diabetes, especially diabetes that isnt well-controlled, can cause inflammation. This may lead to complications in times of illness.

When a diabetic gets sick with any illness, the tendency is for the blood sugar to be elevated, Groen said. The immune system doesnt work as well, and it cant fight it [the illness] very well.

Jan Smith of Joliet saw that firsthand with her husband James V. Smith, who was diagnosed with type 2 diabetes about five years ago. He kept it under good control until he caught the coronavirus, she said.

Jan feels her husbands lack of appetite during his illness might have affected his blood sugar control. She said James was treated in an emergency department on Aug. 31, but his condition continued to worsen.

He went into the hospital on Sept. 8, Jan said. and he died on Sept. 23.

Pazooki said diabetes becomes difficult to manage once the patient becomes severely ill.

In July, the Centers for Disease Control and Prevention published a study of 10,000 people who died from the virus, which further showed the connection between diabetes and COVID-19.

The study found that 49.6% of those aged 65 and up had diabetes as did 35% of those younger than age 65. When compared to people who were white more Hispanic and non-white people were older than 65, the CDC study also said.

But generally speaking, diabetes is more common in people of color and the complications and outcomes are worse, for whatever the reasons might be, Pazooki said.

The CDC study also said more studies are needed to clarify some of the associations, such as those among age, race/ethnicity, SARS-CoV-2 infection, disease severity, underlying medical conditions (especially diabetes) poverty and access to health care and the ability to comply with mitigation recommendations while maintaining essential work responsibilities.

Groen said the longstanding health and social inequities in the U.S. increases the risk in some minority groups, who often have additional chronic conditions, too, such as obesity and high blood pressure.

On top of that, not all types of diabetes are the same and its unclear if the risks are the same.

Certainly high blood sugar plays a role in all forms of diabetes, she said.

A study published April 15 in the Journal of Medical Virology suggests that blood sugars that remain high over time might contribute to the severity of COVID-19 in some people with diabetes.

Pregnant women are also more prone to blood clots, Groen said. In some cases, the SARS-CoV-2 virus also causes blood clots, she added.

What might make Type 2 diabetes particularly troublesome in terms of covid is that it often involves multiple other factors: metabolic syndrome, obesity and even genetics, Pazooki said.

So it is possible that those are other conditions that leads to the type 2 diabetes being more of a bigger risk factor for having adverse outcomes, Pazooki said.

But even treating the coronavirus in a diabetic patient is tricky, Groen said.

If they need steroids, that can elevate the blood sugar, she said.

A study published July 17 in The Lancet said these blood sugar elevations can become quite high, along with an increase insulin resistance, when steroids are administered to a diabetic patient.

Pazooki said diabetics who dont normally take insulin might have their oral diabetes medication temporarily stopped and then switched to insulin if they are being treated for COVID-19 in the hospital.

Oral medication might be harmful if the patient has abnormal kidney function, needs to fast for tests, or has an irregular meal schedule, Pazooki said.

But often this change in treating the diabetes is temporary.

The majority of patients go back home on the medications they came to the hospital with, Pazooki said.

So whats a diabetic to do?

Pazooki suggests diabetics work with their health care providers to keep their condition controlled. Eat a healthy diet, get regular exercise, he said.

Then, hypothetically, outcomes from COVID-19 might be better, he said.

We dont have strong evidence in terms of COVID-19, Pazooki said. But we do have strong evidence in terms of all other types of infectionand COVID-19 is just another infection.

See more here:
Diabetes may not increase your risk of catching the coronavirus - The Herald-News

Six Texas A&M engineering and medical students came together to develop tools to more effectively diagnose diabetic retinopathy.

Texas A&M Engineering

About 10% of the U.S. population has diabetes, and about a third of that number, around 11 million people, will suffer from diabetic retinopathy diabetes-induced irreversible vision loss, at some point in their lifetime. People in both rural and underserved communities may suffer more because they dont have access to specialists, and its likely the disease is underdiagnosed.

Ai-Ris (pronounced A-Iris), a team comprised of six engineering and medical students from Texas A&M University, are working to address these diagnosis barriers. Specifically, they are designing a tool to better reach individuals in rural or underserved communities.

Were developing this system that leverages machine learning and also uses low-cost hardware in a user-friendly form, something like a headset that can be used in a non-clinical setting and doesnt require the presence of an optometrist or ophthalmologist, said T.J. Falohun, team member and biomedical engineering doctoral student.

Uthej Vattipalli, civil engineering graduate student, has personally witnessed the impact of diabetic retinopathy. His grandfather began to lose his eyesight after retirement, but could not afford to get a diagnosis. Vattipalli said the teams work could transform the health care market.

We are going to need an army to go into what we want to do if we want that impact, Vattipalli said. Not everybody has all the skill in the world. Theres definitely been complementary skill sets required to get tasks accomplished. One of the good things of being on an interdisciplinary team is the variety of skill sets that help you keep moving forward.

The project started as a Sling Health initiative.Sling Health National Networkis a student-run biotechnology incubator that provides resources, training and mentorship to teams of students in engineering, medicine and business tackling clinical problems by developing innovative solutions.

The project began to gain members and motivation and spread outside of Sling Health into its entrepreneurship effort. The team continued its work with the help of the Engineering Incubator at Texas A&M, where the students worked with Rodney Boehm, director of Engineering Entrepreneurship, to expand their access to resources.

Now a limited liability company, Ai-Ris placed second in the 2020 Sling Health Demo Day and participated in the Innovation Corps Site Fellows program at Texas A&M. The team also recently won a VentureWell E-team Grant. Through VentureWell, the team will receive funding, connections and training to further their entrepreneurial efforts.

Amir Tofighi Zavareh 19, an electrical engineering doctoral graduate, said beyond making an impact, he joined the team because he is intrigued by the technical challenges involved. He said collecting the retinal images at a low cost is a challenge that is not being addressed in the market.

Right now in the clinics, they use this benchtop device that costs tens of thousands of dollars. Its a very tricky thing to do, Tofighi Zavareh said. We want to do that with low-cost devices, so thats going to make it challenging to do that at the same quality levels but at lower costs so it can be available to rural areas.

Harsha Mohan, a former student and current graduate student studying robotics at Johns Hopkins University, said working on a multidisciplinary team has taught members soft skills such as communicating effectively and elevating each members strengths.

We have people from all over the world; we have people from different backgrounds, and to work toward health care equity at this point of my life, Im not sure theres anything better than this, Mohan said.

Saurabh Biswas, principal investigator of VentureWell Grant and faculty advisor of Sling Health, said Ai-Ris is a great example of a highly motivated team with complementary skill sets, which Biswas said is critical to solve problems in health care.

I truly hope otherAggie innovators will follow their example and take advantage of great programs like VentureWell Grants, Sling Health andNSF I-site and I-Corpto bring their ideas from concept to prototype with extensive customerdiscovery to validate product-market fit, said Biswas, who also serves as executive director of TEES Commercialization and Entrepreneurship and as a professor of practicein the Department of Biomedical Engineering.

While the team continues to delve into the world of entrepreneurship and health care integration, the students are already seeing how their work can play a part in treating many ocular diseases in the future. Marcus Deayala, a biotechnology graduate student, said he is excited to play a part in breaking down barriers to AI diagnostics, which he says will shape the landscape of health care in the future.

I think we all understand that in the richest country (in the world), this many people going blind by a completely avoidable disease is ridiculous, Deayala said. If the level of health care is going to increase, the cost has to come down. We have to become more efficient and devices like these have to be instituted in one way or another.

The rest is here:
Combating Diabetes-Induced Blindness - Texas A&M Today - Texas A&M University Today

HealthCoronavirusHalf a million people were on the waiting list for treatment in Yorkshire and the North East in August, official figures show.

Sunday, 18th October 2020, 11:45 am

The regions, which are often combined for statistical purposes, had an average waiting time of 12 weeks.

Though this is below the Governments pledge of 18 weeks from diagnosis to treatment, 43 per cent of people waited longer, many people significantly so.

The figures show there were some people who waited as long as two years for treatment, with plastic surgery having the longest waiting times.

Cardiothoracic surgery had the shortest waiting times but considerably fewer patients than other areas of medicine.

Ear, nose and throat and opthalmology had the largest number of patients and some of the longest waiting times.

Consulant opthalmic surgeon at Optegra, Shafiq Rehman, told The Yorkshire Post there had been a dramatic increase in cataract referrals in recent months, as people struggled to cope in lockdown with increasingly poor vision, and said he expected waiting times to get worse.

It is highly likely that the additional pressure caused by the fallout from Covid-19 will dwarf the usual seasonal pressures for the NHS and sadly the result is likely to be that elective NHS activity - routine out-patient appointments, cataract surgery, elective hip/knee surgeries - will be most heavily affected and I foresee many areas of the UK experiencing long delays to access routine elective medical care in the coming six to twelve months ahead.

He urged people with medical concerns not to risk making problems worse by delaying seeing a doctor.

Read the original here:
Half a million people in Yorkshire waiting for hospital treatment - this surgery has the longest waiting times - Yorkshire Post

As health systems are set to start reporting their third quarter earnings results this week, new research highlights hospitals' ongoing fears about financial viability, patient volumes and supply stocks.

That's as new hotspots in the Midwest report rising COVID-19 case loads and hospitals prepare for the pandemic to collide with flu season, potentially causing stress on capacity once again.

The takeaway is that most hospitals aren't expecting a return to normal anytime soon, although it depends on the trajectory on ongoing efforts to develop vaccines and treatments. Most executives see 2022 as the timeline for seeing some regularity, according to Kaufman Hall.

About 20% of hospital executives surveyed by the group recently said they were "extremely concerned" about their financial viability until an effective vaccine or treatment is available. Another 50% said they were "moderately concerned."

Some major hospital systems, however, have not fit this pattern. Earlier this month, HCA Healthcare previewed better-than-expected third quarter financial results and said it was returning all $6 billion it received from CMS in federal COVID-19 relief funding.

How health systems are doing now depends larger on their status at the beginning of this year, as well as market position and size, Lance Robinson, managing director at Kaufman Hall and one of the report's authors, said.

"If you were strong going into the COVID crisis, you're probably able to weather it much better than if you were teetering on low margins and low volumes to begin with," he said. "So I think it really just exposed those health systems and providers that were already not doing well."

Meanwhile, patient volumes are falling again after a rebound in early fall. And older people at a higher risk for severe symptoms from COVID-19 are less likely to return for care, according to a Kaiser Family Foundation analysis of Epic EHR data.

That research showed that total admissions for this year will come in about 10% lower than had been forecast, possibly more if restrictions on elective procedures are reinstituted later this year.

"[I]f the coronavirus begins to spread more rapidly later in the fall and non-emergency procedures are once again delayed, it could have serious consequences both for hospitals' financial stability and the health of patients," according to the report.

Outpatient volumes are also rebounding at a varying rate, according to a Commonwealth Fund report published last week. While some areas like dermatology and opthalmology are seeing rates actually exceed pre-pandemic levels, most are still falling short. Pulmonology, for example, is 20% below pre-pandemic levels still.

Multiple reports have shown crashes in pediatric visits, putting a strain on children's hospitals across the country.

Hospital executives are also dealing with changes in workforce and expenses. Three-quarters told Kaufman Hall they are ramping up monitoring and resources going toward mental health and burnout concerns among staff.

They noted that costs for personal protective equipment and labor expenses for nursing staff have increased significantly.

The Kaufman Hall survey conducted in August found 40% saying case numbers are rising and 36% saying they're staying level. Nearly half said the length of stay among COVID-19 patients had led to them canceling elective procedures.

That isn't likely to have improved in the past two months. Eight states set new records last week for novel coronavirus infections recorded in a single day, according to the COVID Tracking Project, and fears about another surge in the coming weeks abound.

Volumes are also varying by service area. About 60% of respondents said oncology levels had returned to 90% of what they were before the pandemic. Not quite half said the same about cardiology surveys while orthopaedics, neurology and radiology trailed at 37% reporting nearly normal volumes. Pediatrics was in the last at 22%

Executives said they are worried about the expected changes in payer mix. The biggest concern is an increase is uncompensated care, followed by higher percentage of self-pay and Medicaid patients.

Those concerns are far from unfounded. At the beginning of this month, more than 4 million people had enrolled in Medicaid because of the pandemic and resulting recession. And more than 14 million may have lost health coverage because of job losses.

To help offset those adjustments, executives are turning to supply reprocessing most, according to Kaufman Hall.After that, nearly 60% said they implemented furloughs and 56%instituted salary freezes or reductions. That was followed by permanent workforce reduction (31%), suspending matching contributions to retirement plans (25%) and restructuring physician contracts (19%).

Permission granted by Kaufman Hall

Supply chain concerns have not entirely waned. In recent months, hospitals have been focused on building up stockpiles of personal protective equipment to prepare for potential case surges. Some states, like California and New York,have mandated they have a 90-day supply on hand.

That presents a new challenge of logistics and warehouse management, said Jeff Ashkenase, group vice president at group purchasing organization Premier.

Providers are generally feeling much better about their access to PPE than they did in March and April, but they may never feel secure that they have enough of everything that could be needed, he said.

"So, we're sort of operating in peril," he said. "We're operating in normal cases and volumes and the types of work that we did and simultaneously building up the stockpile."

Only 3% of hospital staff responding to a recent survey from Premier said accessing the Strategic National Stockpile through their state was an "easy process." About 30% said it was difficult, while 44% said they "managed" and 22% did not access the national stockpile.

Ashkenase called for more coordination to improve the efficiency of shared stockpiles. "With all the stockpiles, the need for more transparency on what's in the stockpile and how to access it, when you will get it, will be beneficial," he said.

Respondents to Premier said regulatory flexibility had been most helpful to them in preparing for another wave. Expanded telehealth coverage and payment was cited the most, followed by reimbursement for alternative care settings and workforce changes like allowing clinicians to practice at the top of their license.

As major public hospital operators begin their Q3 earnings reports with Tenet leading the pack Tuesday, Robinson said he'll be watching for what areas are seeing patients returning and how quickly.

"And then on the expense side, it's obviously the PPE and the staffing requirements that are going to need to be out there, especially if we have a third wave of COVID," he said.

And looking even farther out, the traditional method of looking to the past year's metrics won't work when looking toward 2021 and 2022, Robinson said.

"I think clients are struggling with, 'How do I even begin to build a budget for 2021? What does that look like?'" he said.

Originally posted here:
Providers' rocky road to recovery could last into 2022 - Healthcare Dive

Connective Tissue Growth Factor Market Overview 2020 2025

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

The risingtechnology in Connective Tissue Growth Factor Marketis also depicted in thisresearchreport. Factors that are boosting the growth of the market, and giving a positive push to thrive in the global market is explained in detail.

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/167828

Key Competitors of the Global Connective Tissue Growth Factor Market are:BLR Bio LLCFibroGen IncProMetic Life Sciences IncRXi Pharmaceuticals Corp

Historical data available in the report elaborates on the development of the Connective Tissue Growth Factor on national, regional and international levels. Connective Tissue Growth Factor Market Research Report presents a detailed analysis based on the thorough research of the overall market, particularly on questions that border on the market size, growth scenario, potential opportunities, operation landscape, trend analysis, and competitive analysis.

Major Product Types covered are:BLR-200IB-DMDOLX-201PBI-4050Others

Major Applications of Connective Tissue Growth Factor covered are:Hypertrophic ScarsOpthalmologyGenetic DisordersLiver FibrosisOthers

This study report on global Connective Tissue Growth Factor market throws light on the crucial trends and dynamics impacting the development of the market, including the restraints, drivers, and opportunities.

The fundamental purpose of Connective Tissue Growth Factor Market report is to provide a correct and strategic analysis of the Connective Tissue Growth Factor industry. The report scrutinizes each segment and sub-segments presents before you a 360-degree view of the said market.

Market Scenario:

The report further highlights the development trends in the global Connective Tissue Growth Factor market. Factors that are driving the market growth and fueling its segments are also analyzed in the report. The report also highlights on its applications, types, deployments, components, developments of this market.

Highlights following key factors:

:-Business descriptionA detailed description of the companys operations and business divisions.:-Corporate strategyAnalysts summarization of the companys business strategy.:-SWOT AnalysisA detailed analysis of the companys strengths, weakness, opportunities and threats.:-Company historyProgression of key events associated with the company.:-Major products and servicesA list of major products, services and brands of the company.:-Key competitorsA list of key competitors to the company.:-Important locations and subsidiariesA list and contact details of key locations and subsidiaries of the company.:-Detailed financial ratios for the past five yearsThe latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Our report offers:

Market share assessments for the regional and country level segments. Market share analysis of the top industry players. Strategic recommendations for the new entrants. Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets. Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations). Strategic recommendations in key business segments based on the market estimations. Competitive landscaping mapping the key common trends. Company profiling with detailed strategies, financials, and recent developments. Supply chain trends mapping the latest technological advancements.

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://reportsinsights.com/industry-forecast/Connective-Tissue-Growth-Factor-Market-167828

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

The rest is here:
Connective Tissue Growth Factor Market, Share, Application Analysis, Regional Outlook, Competitive Strategies & Forecast up to 2025 - The Think...

Culture Books

The e-book debut also delivers all new Pinoy monstersmeaning none of your usual aswangs and tikbalangs.

Halloween is just around the corner, and since youll most likely be spending the spooky celebration at home, you might as well curl up with a good horror book. Writer, musician, filmmaker and podcaster Wincy Aquino Ong has released his first collection of short fiction entitledTales For A Rainy Season. If youre looking for fresh new scares, this might be the reading material for you.

Ive always been a fan of Rod SerlingsThe Twilight Zone,says the 38-year-old. So I thought to myself: I want to write a book thats sort of a Pinoy version ofThe Twilight Zonemix in the supernatural with mundane details all Filipinos can relate to, and end the story with a note the reader wasnt expecting.

In writing the book, Ong challenged himself to steer clear of whats been done before in Filipino horror fictionthe aswangs, the white ladies, the tikbalangs that are common fixtures in the genre.

Apparently, theres still a lot to be mined in Pinoy horror culture after youve gone past the aswangs from Siquijor, the White Lady from Balete Drive, and the Snake Man in Robinsons Galleria, says Ong. I looked deeper into the annals of our local folklore and urban legends, these rabbit holes on the Internet, and I found so many obscure gems that a horror writer can easily turn into a short story.

Tales for a Rainy Seasonclaims it has everythingfrom Nardong Putik (the gangster who could turn himself invisible by using consecrated mud) to Baguio hippies who practice ritual suicides. One of the stories explores that urban legend of Jose Rizal being the man behind the Whitechapel Murders.

Entitled The Opthalmologists Case, Ongs alternate take on the Sherlock-Holmes-meets-Rizal story comes from all the Rizaliana he imbibed from prep to college in Ateneo de Manila. Marilou Diaz-Abaya, one of Ongs teachers and the director of the 1998 epic on the National Hero, also shared with Ongs class the wealth of information she discovered while working on the biopicstuff not usually included in a Rizal class.

One of the pieces of trivia from those classes thats stayed with Ong is Rizals stint as a horror writer. He wrote one calledJunto al Pasig, which is like aStranger Thingsadventure tale where a group of kids fight Satan during a Holy Week procession. Truly cool stuff, says theTales for A Rainy Seasonauthor.

Which brings us back to The Opthalmologists Case. I wanted to explore that urban legend that connected Rizal to the Jack the Ripper murders in 1888. Historically speaking, he was there in London when it all happened! And since Im a big Sherlock Holmes fan, I couldnt think of any other detective who could dig up the case...I pictured more as a fugitive movie, where Rizal is on the run from the law, and Sherlock and Watson are on his tail.

Ong describes the story as an exciting chase through the many corners of 19th century London, and via the story, readers will get a glimpse of the life of an Ilustrado in those timesthe boarding houses, their habits and vices, the nightlife in the seedier parts of the city. More than that, I wrote the story because I wanted to see how the smartest Filipino there ever was can match up to the terrifying mind that is Sherlock Holmes.

Ong is not exactly a stranger to the horror genre. He is the writer and director behind the 2011 Cinemalaya horror filmSan Lazaroand 2014sOvertimeunder GMA Films.For him, a good horror story should have other things going for it than the scares. A good horror story must also have humor and drama.Also, it all boils down to the hero of your story and how much you care for him or her, says the author. Before you expose your hero to the ghost or the monster, he should be someone you root for and care about.

Tales for a Rainy Season,now available for download at the Amazon Kindle Store and Kindle Unlimited.

Read more here:
Sherlock Holmes meets Jose Rizal in this debut horror story collection - ABS-CBN News

In a recent clinical trial for an immune cell therapy for lymphoma, 62% of patients experienced complete cancer clearance in spite of the fact that some of them were on their 5th line of treatment. Stem cell therapies have the potential to enact more of these paradigm-shifting treatments. Proposition 14 will continue to advance these therapies and bring them to full development as available cures.

The vision of stem cell therapy is that a physician can just as easily grab an IV bag full of therapeutic cells as they might draw a drug into a syringe. Conceived through Proposition 71 in 2004, the California Institute for Regenerative Medicine (CIRM) serves as a vehicle to support all aspects of stem cell research. Medical progress requires not just well-designed clinical studies but also a well-trained workforce, educated at the intersection of stem cell biology, engineering, and chemistry.

Since 2008, CIRM has supported the training of nearly 1300 Community College and California State University students for the emerging field of Regenerative Medicine through the Bridges to Stem Cell Research and Therapy Program. The Bridges Training Program has functioned as a pathway for first-generation and underrepresented students from Humboldt to San Diego, to all of the biomedical sectors startup and cell therapy companies, academic research institutes, graduate and medical school, and more. Exposure to hands-on labs, advanced seminar discussions, and a required paid internship fully prepares these students for entering the stem cell workforce. Over 80% of Bridges alumni have either advanced to graduate school or joined the biomedical workforce in industry or academic institutions. These Programs bring a greater return than the initial cost of training.

SPONSORED

Consider Vahid Hamzeinejad, a bright high school student, headed to UC Berkeley to begin his college career. Enter the Great Recession; Vahid found himself back at home, working non-stop to help keep his parents restaurant afloat. Not giving up on his commitment to an education, he enrolled at the College of the Canyons. After completing an Associates degree, Vahid transferred to Cal Poly, hoping to join the Bridges Program. After receiving the Bridges core training, Vahid started his internship at ViaCyte, where he continues to work today, as a critical member of the team supporting ViaCytes clinical development of a functional cure for diabetes. The nearly $30 billion that California currently spends on diabetes treatments could be significantly reduced, in no small part due to the efforts of a student that cost taxpayers $36,000 to educate. That is before considering the benefit to patients quality of life that would occur by replacing insulin pumps, glucose monitors, and constant vigilance with a stem-cell-derived tissue that regulates blood sugar levels biologically making and secreting its own insulin.

Passing Proposition 14 will enable this and other unparalleled treatments for diabetes, heart disease, cancer, and neurological disorders.

Signed,

Robert Kam and the CIRM Bridges Program

SPONSORED

Continue reading here:
CIRM Bridges to Stem Cell Research & Therapy The Bridge to Everywhere (in biomedicine) OP-ED - The Silicon Valley Voice

InvestorPlace

In late September, a U.S. House vote to remove marijuana from the federal Controlled Substances Act was delayed until after the presidential election. If the House remains controlled by Democrats, industry analysts expect the Marijuana Opportunity Reinvestment and Expungement (MORE) Act to potentially pass before the end of 2020. Then, it would be up to the Senate to possibly take a similar action. Today, we will look at three marijuana stocks to buy with decriminalization in the agenda.Canada is the first and only G7 nation to have legalized cannabis nationwide. In the U.S., at the federal level, marijuana is illegal and remains a Schedule I drug. Legal status varies at the state level. However, Democratic vice president nominee Kamala Harris has recently said marijuana would be decriminalized at the federal level under a Biden administration.2018 saw excessive speculation in marijuana stocks. Yet since 2019, a wide range of issues have affected the cannabis industry. Recreational cannabis sales in Canada hit significant headwinds and never reached the levels investors hoped. Although revenue improved for some companies, they have yet to become profitable. And cash burn remains concerning. As a result, most marijuana stocks have been on a roller coaster ride and hit new lows. Put another way, the bubble has burst.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAccording to recent research led by Douglas Berman of Ohio State University, the COVID-19 pandemic has both introduced tremendous new challenges for the cannabis industry and exacerbated long-standing difficulties for businesses in this arena.7 Value Stocks to Buy in an Overvalued MarketNonetheless, with difficulties usually come new opportunities while industry leaders and innovations may appear. With that information, here are three marijuana stocks that could benefit from U.S. developments at the federal level:Constellation Brands(NYSE:STZ)ETFMG Alternative Harvest ETF(NYSEARCA:MJ)GW Pharma(NASDAQ:GWPH)Marijuana Stocks: Constellation Brands(STZ)Source: ShinoStock / Shutterstock.comConstellation Brands is best known as a leading producer and marketer of alcoholic beverages. It holds a large portfolio of beer, wine and distilled spirits brands. Several of those well-recognized brands include Corona, Modelo, Robert Mondavi, Svedka vodka, Casa Noble tequila and High West whiskey. It is one the fastest-growing large consumer packaged goods companies stateside. Outside the U.S., it has operations in Italy, Mexico and New Zealand.The Victor, New York-based group is on our list of marijuana stocks because in 2018, it took a large stake in Ontario, Canada-based Canopy Growth(NYSE:CGC), one of the leading Canadian marijuana producers. STZs 38%-stake in CGC means the latter now has considerable managerial and financial backing.So far, this equity stake in Canopy Growth has been an earnings drag for Constellation Brands, and it will likely remain so in the near future. However, any potential improvement in the outlook of the pot sector in Canada and the U.S. could easily benefit STZ stock. Therefore, this indirect play on CGC could be a less risky approach for many investors.Year-to-date, STZ stock is down about 1.5%. However, that metric tells only half the story. Since the lows hit in early spring, the stock is up about 80%. The current forward price-earnings and price-sales ratios stand at at 20.88 and 4.78 respectively. Wed look to buy the the dips in price, especially if there is a decline toward the $175 level.ETFMG Alternative Harvest ETF (MJ)Source: ShutterstockThe ETFMG Alternative Harvest ETF offers exposure to Canadian cannabis producers as well as a number of firms with exposure to the industry, albeit indirectly. Thus the fund could be appropriate for long-term investors who are interested in the pot sector, but would like to have access to a diverse range of companies.MJ, which has 37 holdings, tracks the Prime Alternative Harvest index. Canopy Growth, Cronos (NASDAQ:CRON), and Tilray (NASDAQ:TLRY) top the list of holdings. Top-10 names make up around half of net assets, which stand around $550 million. The ETF was launched in 2015.7 Value Stocks to Buy in an Overvalued MarketSo far this year, the fund is down more than 30% and hit an all-time low in March. Since 2019, MJ has lost considerable value, driven by the industrys weakness and poor earnings by most pot companies. These stocks tend to be very choppy when their quarterly earnings are due. Given the volatility in the sector, long-term investors should be ready for large short-term price fluctuations in the fund. The sector is risky, but MJs diversification makes it safer than many alternatives.GW Pharma (GWPH)Source: ShutterstockOur final marijuana stock is the cannabis-focused biotech GW Pharma. According to a recent report by the United Nations, Britain is the biggest producer and exporter of legal cannabis in the world. And almost all of the exports are in a single drug, i.e., Sativex, produced by the UK-based GW Pharma. It is used to treat spasms in multiple sclerosis patients.Earlier in the year, the U.S. Drug Enforcement Administration also descheduled Epidiolex, another one of the companys products. As a result, it is no longer listed as a controlled substance stateside. In August, the U.S. Food and Drug Administration approved it to treat seizures in tuberous sclerosis complex.GW is also one of MJs largest holding, accounting for 6.41% of its assets. GWPH stock could be an alternative way to get exposure to the cannabis industry. Year-to-date, the shares are down around 8%. A potential decline toward $90 or below would improve the safety margin for long-term investors.On the date of publication, Tezcan Gecgil did not have (either directly or indirectly) any positions in the securities mentioned in this article.TezcanGecgil has worked in investment management for over two decades in the U.S. and U.K. In addition to formal higher education in the field, she has also completed all 3 levels of the Chartered Market Technician (CMT) examination. Her passion is for options trading based on technical analysis of fundamentally strong companies. She especially enjoys setting up weekly covered calls for income generation. She also publisheseducationalarticles on long-term investing.More From InvestorPlaceForget The Election Pick These Stocks for the Win in 2021Why Everyone Is Investing in 5G All WRONGAmericas #1 Stock Picker Reveals His Next 1,000% WinnerRevolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 CompanyThe post 3 Marijuana Stocks to Buy With Decriminalization on the Table appeared first on InvestorPlace.

Read more from the original source:
Former NFL Players Show Interest in Regenerative Medicine and Cell Therapies - Yahoo Finance

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Regenerative Medicine Market.

Trusted Business Insights presents an updated and Latest Study on Regenerative Medicine Market. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Regenerative Medicine Market during the forecast period.It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Regenerative Medicine Market Size, Share and Industry Analysis By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By Application (Orthopaedics, Wound Care, Oncology), By Distribution Channel (Hospitals, Clinics) & Regional Forecast, 2020 2029 (Includes COVID-19 Business Impact)

We have updated Regenerative Medicine Market with respect to COVID-19 Business Impact.Inquire before buying

This report focuses on the Regenerative Medicine market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Regenerative Medicine market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.

Global Regenerative Medicine Market: Segment Analysis

The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.

Global Regenerative Medicine Market: Regional Analysis

The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.

Global Regenerative Medicine Market: Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.List of Companies Profiled

Report Coverage

The potential to directly alter human genes was first recognized nearly more than 50 years ago. Cell and gene therapy, represent overlapping fields of biomedical research with similar therapeutic goals. Regenerative medicine also comprises of therapeutic tissue engineering and biomaterials -engineered substances used in medical applications to supplement or replace a natural body function. The increased number of the clinical trials and the use of the regenerative medicine for the development of the medicine to treat chronic diseases are some of the factors propelling the regenerative medicine market trends.

The report provides qualitative and quantitative insights on the regenerative medicine industry trends and detailed analysis of market size and growth rate for all possible segments in the market. The market is segments include type, application, distribution channel, and geography. On the basis of the type, the market is segmented into cell therapy, gene therapy, tissue engineering and platelet rich plasma. On the basis of the application, the market is segmented into orthopedics, wound care, oncology and others. On the basis of distribution channel, the regenerative medicine market is segmented into hospitals, clinics and others. Geographically, the market is segmented into five major regions, which are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions are further categorized into countries.

Along with this, the regenerative medicine market report comprises analysis of the industry dynamics and competitive landscape. Various key insights provided in the report are prevalence and incidence of diabetes by key countries, advancements in insulin delivery devices, recent industry developments such as mergers & acquisitions, pricing analysis, technological advancements, and key industry trends.

SEGMENTATION

By Product

By Application

By Distribution Channel

By Geography

Key Industry Developments

In September 2020, Takeda Pharmaceutical Company Limited announced the expansion of its cell therapy manufacturing capabilities with the opening of a new 24,000 square-foot R&D cell therapy manufacturing facility at its R&D headquarters in Boston, Massachusetts. The facility provides end-to-end research and development capabilities and will accelerate Takedas efforts to develop next-generation cell therapies, initially focused on oncology with the potential to expand into other therapeutic areas.

The R&D cell therapy manufacturing facility will produce cell therapies for clinical evaluation from discovery through pivotal Phase 2b trials. The current Good Manufacturing Practices (cGMP) facility is designed to meet all U.S., E.U., and Japanese regulatory requirements for cell therapy manufacturing to support Takeda clinical trials around the world.

Takedas Cell Therapy Translational Engine (CTTE) connects clinical translational science, product design, development, and manufacturing through each phase of research, development, and commercialization. It provides bioengineering, chemistry, manufacturing, and control (CMC), data management, analytical, and clinical and translational capabilities in a single footprint to overcome many of the manufacturing challenges experienced in cell therapy development.

In 2018, Novartis received EU approval for one-time gene therapy Luxturna, which has been developed to restore vision in people with rare and genetically-associated retinal disease.

In 2018, Novartis received EU approval for its CAR-T cell therapy, Kymriah.In 2017, Integra LifeSciences launched its product, Integra Dermal Regeneration Template Single Layer Thin for dermal repair defects reconstruction in a one-step procedure.

Looking for more? Check out our repository for all available reports on Regenerative Medicine Market in related sectors.

Quick Read Table of Contents of this Report @ Regenerative Medicine Market Size, Share and Industry Analysis By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By Application (Orthopaedics, Wound Care, Oncology), By Distribution Channel (Hospitals, Clinics) & Regional Forecast, 2020 2029 (Includes COVID-19 Business Impact)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Original post:
Regenerative Medicine Market Size, Share and Industry Analysis By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By...

Gosselies, Belgium, 12 October 2020, 7am CEST BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announce that CEO, Miguel Forte, MD, PhD will present at the annual Cell & Gene Meeting on the Mesa to be held virtually October 12-16. Miguel Forte will also chair the session The European Regulatory Environment for ATMPs Should we expect more or less regulation? with the participation of panelists from the European Organization for Rare Diseases (EURORDIS), the European Medicines Agency (EMA) and the European Commission.

Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a five-day virtual conference featuring more than 120 dedicated company presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies. The meeting also includes over 100 panelists and featured speakers taking part in 20 in-depth sessions covering all aspects of cell and gene therapy commercialization. Companies presentations will be available to view on-demand throughout the entirety of the conference

Please visit http://www.meetingonthemesa.com for full information including registration. Complimentary attendance at this event is available for credentialed investors and members of the media only. Investors should contact Laura Stringham at lstringham@alliancerm.org and interested media should contact Kaitlyn Dupont at kdupont@alliancerm.org.

About Bone Therapeutics

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and other diseases. The Company has a, diversified portfolio of cell and biologic therapies at different stages ranging from pre-clinical programs in immunomodulation to mid-to-late stage clinical development for orthopedic conditions, targeting markets with large unmet medical needs and limited innovation.

Bone Therapeutics is developing an off-the-shelf next-generation improved viscosupplement, JTA-004, which is currently in phase III development for the treatment of pain in knee osteoarthritis. Consisting of a unique combination of plasma proteins, hyaluronic acid - a natural component of knee synovial fluid, and a fast-acting analgesic, JTA-004 intends to provide added lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic pain and inflammation. Positive phase IIb efficacy results in patients with knee osteoarthritis showed a statistically significant improvement in pain relief compared to a leading viscosupplement.

Bone Therapeutics core technology is based on its cutting-edge allogeneic cell therapy platform with differentiated bone marrow sourced Mesenchymal Stromal Cells (MSCs) which can be stored at the point of use in the hospital. Currently in pre-clinical development, BT-20, the most recent product candidate from this technology, targets inflammatory conditions, while the leading investigational medicinal product, ALLOB, represents a unique, proprietary approach to bone regeneration, which turns undifferentiated stromal cells from healthy donors into bone-forming cells. These cells are produced via the Bone Therapeutics scalable manufacturing process. Following the CTA approval by regulatory authorities in Europe, the Company is ready to start the phase IIb clinical trial with ALLOB in patients with difficult tibial fractures, using its optimized production process. ALLOB continues to be evaluated for other orthopedic indications including spinal fusion, osteotomy, maxillofacial and dental.

Bone Therapeutics cell therapy products are manufactured to the highest GMP standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. The Company is based in the BioPark in Gosselies, Belgium. Further information is available at http://www.bonetherapeutics.com.

For further information, please contact:

Bone Therapeutics SAMiguel Forte, MD, PhD, Chief Executive OfficerJean-Luc Vandebroek, Chief Financial OfficerTel: +32 (0)71 12 10 00investorrelations@bonetherapeutics.com

For Belgian Media and Investor Enquiries:BepublicCatherine HaquenneTel: +32 (0)497 75 63 56catherine@bepublic.be

International Media Enquiries:Image Box CommunicationsNeil Hunter / Michelle BoxallTel: +44 (0)20 8943 4685neil.hunter@ibcomms.agency / michelle@ibcomms.agency

For French Media and Investor Enquiries:NewCap Investor Relations & Financial CommunicationsPierre Laurent, Louis-Victor Delouvrier and Arthur RouillTel: +33 (0)1 44 71 94 94bone@newcap.eu

For US Media and Investor Enquiries:LHA Investor RelationsYvonne BriggsTel: +1 310 691 7100ybriggs@lhai.com

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such persons officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Continue reading here:
Bone Therapeutics to present at 2020 Virtual Cell & Gene Meeting on the Mesa - GlobeNewswire

Immuno-oncology and CAR T cells energized the field of regenerative medicine, but for cell and gene to deliver on their promises, new, disruptive technologies and new modes of operation are needed. Specifically, that entails improving manufacturing to control variables and thus ensure product consistency, and maturing the regulatory environment to improve predictability.

Manufacturing cells is not like manufacturing small molecules, Brian Culley, CEO of Lineage Cell Therapeutics, told BioSpace. For cell therapy products to mature into real products that deliver on the promises of 10 years ago, they must be scalable which drives affordability and they must solve their purity issues.

On the clinical side, cell and gene therapies must find places where small molecules, antibodies or other traditional approaches may not be the best option.

For example, The era of transplant medicine is unfolding before us, Culley said. Because of the transplant component, cell therapy may enable changes the body never could do alone.

Lineage is addressing dry AMD and spinal cord injuries with two of its therapeutics.

Our approach is fundamentally different from traditional approaches. We replace the entire cell rather than modulate a pathway. There is a rational hypothesis where cell therapy can win, but first we need to fix the operational hurdles, Culley said.

To address the manufacturing challenges, Culley said, We work only with allogeneic approaches. For us, not being patient-specific is a huge advantage.

Not long ago, the industry was focused on 3D manufacturing in bioreactors.

Were beyond that, Culley said. For our dry AMD product, we can manufacture 5 billion retinal cells in a three liter bioreactor. The advantage is that the cells exist in a very homogenous space and are 99% pure.

As a result, they are more affordable and can be harvested with little manipulation.

Manual manipulation affects gene expression, he pointed out, so minimizing that, as well as the vast quantities of plastics typically required, results in a more controlled process and a more consistent product.

Additionally, Lineage introduced a thaw and inject formulation, so the cell therapy can be thawed in a water bath, loaded into a chamber and injected, all within a few minutes. Traditional dose administration requires washing, plating and reconstituting the cells the before they are administered to a patient.

Getting rid of the prior day dose prep is one example of the maturation of the field, which we are deploying today to help usher in a new branch of medicine, Culley said.

At Lineage, were tackling problems that largely were intractable. For dry AMD, theres nothing approved by the FDA. No one know why the retinal cells die off, so we manufacture brand new retinal cells (OpRegen) and implant them, Culley said. Were seeing very encouraging clinical signs, including the first-ever case of retinal restoration.

Retinal cells compose a thin layer in the back of the eye, Culley explained.

They start to die off in one spot, and that area grows outward. When we inject our manufactured cells where the old ones died, weve seen the damaged area shrink and the architecture in previously damage areas completely restored, Culley said. Weve treated 20 patients for dry AMD in, ostensibly, safety trials, but you cant help but notice efficacy when a patient reads five more lines on an eye chart. Its hard to imagine our intervention wasnt responsible for that, especially when humans cant regenerate retinal tissue.

The spinal injury program (OPC1) may represent an even greater breakthrough. As with dry AMD, there is no FDA-approved therapy.

We manufacture oligodendrocytes and transport them into the spinal cord, to help produce the myelin coating for axons, he told BioSpace. Because of the oligodendrocytes, the axons grow, become myelinated, and begin to function. Small molecule and antibody therapies havent been able to do that.

So far, 25 people have been treated in a Phase I/II trial. Culley reported cases in which a quadriplegic man, after OPC1 therapy, is now typing 30 to 40 words per minute, and another who now can throw a baseball. Its not unusual for patients who initially were completely paralyzed to now schedule their treatments around college classes, Culley said.

Humans can have varying degrees of recovery from spinal cord injury, but these are higher than we would expect, Culley said.

Other cell and gene companies are advancing solutions, too.

Many companies with induced pluripotent stem cells (iPSCs) are trying to figure out how to get scalability, purity, and reproducibility to work for them. Its not a quick fix, he said.

One of the challenges is balancing the clinical and manufacturing aspects of development.

If you have a technology thats not yet commercially viable, but you have clinical evidence, its tempting to focus on the clinical side, Culley said.

Too many companies do that, and then find their candidate must be reworked for scale up. Therefore, consider scale up and manufacturing early.

Theres a need for balance at a more granular level, too. For example, he asked, How many release criteria do you need? Just because you know a cell expresses a certain surface marker, does that add to your process? Ive seen companies ruined by trying to be perfect, and others by rushing headlong, seeing evidence where evidence doesnt exist.

As Lineage matures its processes to support larger clinical trials, the greatest challenges have been time It takes 30 to 40 days to grow cells, Culley said and regulatory uncertainty. Often, there is no regulatory precedence so there are holes to be addressed. For example, cell and gene therapies sometimes have a delivery component such as a scaffold or delivery encapsulation technology that also must be considered. Real-time regulatory feedback isnt available, so you proceed, presuming that what youre doing will be acceptable to regulators.

The FDA recognizes that new, disruptive technologies and approaches are being used, and must be used, for cell and gene therapy to reach patients.

The FDA is responsive and is trying to push guidance out, Culley said, but it takes time.

Visit link:
Disruptive Technologies and Mature Regulatory Environment Vital for Cell Therapy Maturation - BioSpace

Woolly worm race champion to predict winter weather this upcoming seasonNews / 8 hours ago

Hard Rock International, Bristol Chamber of Commerce host job information session for proposed casinoNews / 8 hours ago

Hundreds attend 'Trump Train Parade' in Sullivan County SaturdayNews / 8 hours ago

60th annual Southeastern Autorama returns to ErwinNews / 8 hours ago

Medical cannabis processor Dharma Pharma opens to patients in Bristol, VirginiaNews / 8 hours ago

The Volunteer Bus: Give back, Go Vols!News / 2 days ago

UPDATE: Police identify 3 dead after Saturday morning shootingNews / 8 hours ago

Trump Train Parade to go from Bristol to KingsportNews / 1 day ago

Hard Rock executives hold event for women and young professionals ahead of Bristol casino referendumNews / 1 day ago

Court TV interviewed Anslee Daniel regarding Evelyn Boswell case Friday nightNews / 1 day ago

Ballad leader: Fresh spike in COVID deaths likely four to six weeks awayNews / 1 day ago

Tennessee leaders to make adjustments to teacher accountabilityNews / 2 days ago

Continued here:
Woolly worm race champion to predict winter weather this upcoming season - WJHL-TV News Channel 11

As health sciences researchers conduct clinical trials to develop safe and effective therapies and vaccines for COVID-19, two nontrial pre-approval access pathways expanded access and right-to-try are becoming more widely-known to the general public.

A study published in Regenerative Medicine written by University of Minnesota Associate Professor Leigh Turner, Simon Fraser University Professor Jeremy Snyder, and New York University Assistant Professor Alison Bateman-House suggests thatmost patients engaged in online crowdfunding and seeking nontrial preapproval access to investigational medical products obtain them using the expanded access regulatory pathway rather than through what is known as the right-to-try.

The federal Right To Try (RTT) Act became law in 2018. It allows for individuals with life-threatening diseases to access investigational medical products if they:

Supporters, including President Trump, promote the right-to-try option as an important pathway for obtaining access to investigational medical products, said Turner, who is with the U of Ms Center for Bioethics. To date, however, few individuals appear to be obtaining access to such products on a right-to-try basis. Right-to-try has been promoted as a faster and less bureaucratic alternative to expanded access.

However, our research findings suggest that when it comes to crowdfunding campaigns on GoFundMe, references to right-to-try often reflect a poor understanding of nontrial preapproval access. In reality, at least according to the crowdfunding campaigns we examined, expanded access is the route by which individuals more commonly access investigational products outside clinical trials.

Expanded access, while also providing access to investigational medical products provided outside clinical trial context, differs significantly from the right-to-try pathway in that it requires FDA and institutional review board (IRB)oversight. The FDA and the IRB review submitted requests and decide if an investigational medical product should be provided on an expanded access basis. President Trump, for example, recently obtained access to an investigational product for COVID-19 a monoclonal antibody cocktail on an expanded access basis.

The experimental interventions allowed under the RTT Act and through an expanded access basis are not commonly covered by insurers. As a result, many individuals engage in online crowdfunding activity to cover the often substantial costs associated with accessing investigational interventions provided outside clinical trials.

Turner and his co-authors identified 79 GoFundMe campaigns referencing right-to-try and 115 campaigns referencing expanded access between April 2019 and April 2020. These campaigns also discussed seeking experimental medical interventions in the U.S.

When restricting analysis to campaigns initiated in 2018 and later, which is around the time the RTT Act was made into law, the researchers identified:

Through this study, researchers found that:

It is important to note that the campaigns on GoFundMe list donation goals and funds received but they may not accurately reflect costs associated with seeking access to investigational medical products pursued via expanded access pathway or a right-to-try option. Furthermore, data collected on crowdfunding sites does not necessarily reflect experiences of individuals who seek access to investigational medical products administered outside clinical trials but do not engage in crowdfunding activities.

Acknowledging these limitations, the study does suggest that, in practice, expanded access provides meaningful access to investigational medical products whereas right-to-try is more rhetorical slogan than practical option.

Read more:
Crowdfunding campaigns seeking donations supporting the use of investigational medical products provided via expanded access or 'right-to-try'...